| 放线菌药物资源开发面临的问题与对策 |
| |
| 引用本文： | 姜 怡,徐 平,娄 恺,徐丽华,刘志恒.放线菌药物资源开发面临的问题与对策[J].微生物学报,2008,35(2):0272-0274. |
| |
| 作者姓名： | 姜 怡 徐 平 娄 恺 徐丽华 刘志恒 |
| |
| 作者单位： | (1. 微生物药物国家工程研究中心 云南省微生物研究所 云南大学 昆明 650091)(2. Leibniz-Institut für Meereswissenschaften, IFM-GEOMAR, Düsternbrooker Weg 20, D-24105 Kiel, Germany);微生物药物国家工程研究中心 云南省微生物研究所 云南大学 昆明 650091;新疆农业科学院特殊环境微生物资源重点实验室 乌鲁木齐 830000;微生物药物国家工程研究中心 云南省微生物研究所 云南大学 昆明 650091;中国科学院微生物研究所 北京 100101 |
| |
| 基金项目： | 国家973项目(No.2004CB719601); 科技部国际合作重点项目(No. 2006DFA33550); 国家自然科学基金项目(No.30270004、30560001) |
| |
| 摘 要： | 放线菌药物的开发已取得了极其辉煌的成就, 对医疗事业的发展和人类健康做出了重大贡献。然而, 随着放线菌药物资源的长期开发和利用, 也面临诸多问题。如: 包袱沉重, 去重复难度极大, 因而投资周期长、耗资巨, 风险大; 药物开发赶不上病原菌抗药性的增加及不断出现的新疾病; 虽然未知放线菌甚多, 但发现难度大。为此, 提出了从化学、菌种和基因三方面开展放线菌药物研究的应对策略, 以解决限制放线菌药物资源持续利用和发展的瓶颈。
|
| 关 键 词： | 放线菌 药物开发 |
Problem and Countermeasure on Development of Pharmaceuticals from Actinomycete Resources |
| |
| JIANG Yi,XU Ping,LOU Kai,XU Li-Hua and LIU Zhi-Heng.Problem and Countermeasure on Development of Pharmaceuticals from Actinomycete Resources[J].Acta Microbiologica Sinica,2008,35(2):0272-0274. |
| |
| Authors: | JIANG Yi XU Ping LOU Kai XU Li-Hua and LIU Zhi-Heng |
| |
| Institution: | (1. The National Engineering Center for Research of Microbial Pharmaceuticals, Yunnan Institute of Microbiology, Yunnan University, Kunming 650091) (2. Leibniz-Institut für Meereswissenschaften, IFM-GEOMAR, Düsternbrooker Weg 20, D-24105 Kiel, Germany);The National Engineering Center for Research of Microbial Pharmaceuticals, Yunnan Institute of Microbiology, Yunnan University, Kunming 650091;The Key Laboratory for Microbial Resources in Special Environments, Xinjiang Academy of Agriculture Sciences, Urumchi 830000;The National Engineering Center for Research of Microbial Pharmaceuticals, Yunnan Institute of Microbiology, Yunnan University, Kunming 650091;Institute of Microbiology, Chinese Academy of Science, Beijing 100101 |
| |
| Abstract: | Development of antibiotics from actinomycetes has acquired enormous accomplishment. About 12000 bioactive metabolites were discovered from actinomycetes. Up to now it is very difficult to finding novel compounds with bioactivities from microorganisms. Advance of discovery of new actinomycete species from extreme environments and ocean, integration of modern chemical techniques and database, and genomic techniques are reviewed for meeting the challenge and difficulty in pharmaceutical development from actinomycetes in this paper. |
| |
| Keywords: | Actinomycetes Pharmaceutical development |
|
| 点击此处可从《微生物学报》浏览原始摘要信息 |
| 点击此处可从《微生物学报》下载免费的PDF全文 |
|
